Researchers at the University of Toronto's Temerty Faculty of Medicine have found widespread genetic and protein changes in ...
Researchers at the University of Toronto's Temerty Faculty of Medicine have found widespread genetic and protein changes in ...
The experimental therapy M102 slowed disease progression in preclinical experiments done in mouse and cell models of ALS, a ...
This first-in-class ASO replicates the protective effects of naturally occurring CD33 loss-of-function variants, which are associated with increased resilience to neurodegenerative disease, reduced ...
TDP-43 CYTOPE ® preclinical data demonstrates the potential of Prothena’s CYTOPE technology as a novel modality for delivering large molecules into cells, enabling precise targ ...
As the U.S. Food and Drug Administration (FDA) proposed, Clene is concluding analyses of its ALS biomarker data with completion planned shortly ...
A drug candidate found to protect nerve cells damaged by motor neuron disease (MND), could offer new hope to people living ...
Gnome Sciences, a molecular pathology and translational research services company, announced a significant advance in the fight against ALS (amyotrophic lateral sclerosis). In a newly published study, ...
SPG302 was well tolerated in a trial, with preliminary data supporting the idea the therapy might slow ALS progression.
20d
Answer ALS Completes Release of Full Dataset and Integrates ALS TDI ARC Study Data into Neuromine
Answer ALS today announced the full release of its comprehensive ALS clinical and multi-omics dataset, marking the culmination of a multi-year research program and a groundbreaking collaboration with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback